Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one
Contents

Academy · Research Publication · Using GPP3 in practice

Good Publication Practice: The Requirements of GPP3 and the Changes Introduced in GPP 2022

GPP3 is not merely a statement of principles; it is a set of operational requirements — a written agreement before drafting, authorship determined against the ICMJE criteria, the naming of every contributor, and the disclosure of results irrespective of whether they favour the sponsor. The 2022 update retained all of these requirements and widened the range of research to which they apply.

Pubrica AcademyWritten by the medical writing and biostatistics teams Reviewed byPubrica biostatistics team Published9 October 2026 Last checked9 October 2026 Reading time12 minutes Sources35 peer-reviewed

Most researchers first encounter Good Publication Practice as a line in a contract or an SOP: “this publication will be developed in accordance with GPP.” That line commits authors to specific, verifiable obligations, several of which must be met before drafting begins. This article sets out those obligations in the order in which they arise on a publication and notes where the 2022 update changed them. It is addressed to those who carry out the work rather than to those who sign the policy.

Learning objectives

  • The four requirements GPP3 places on authors before drafting starts, and the consequences when they are omitted
  • How GPP3 and the ICMJE authorship criteria interlock — GPP defers to ICMJE on authorship and adds the sponsor’s obligations around it
  • What the GPP 2022 update changed in scope, and what it deliberately left alone
  • Why declared professional writing support is the opposite of ghostwriting, with the reporting-quality evidence from Gattrell and colleagues
  • How to write an acknowledgement that withstands editorial scrutiny rather than prompting a query
  • Which GPP3 requirements are enforceable by a journal and which are enforceable only by the author’s own organisation

Common misconceptions

  • “GPP is a voluntary code, so it has no teeth.” Most of its authorship, acknowledgement, funding-disclosure and registration requirements are also journal submission conditions. Failure to meet them leads to rejection or correction of the paper, irrespective of GPP’s own status.
  • “GPP3 is an industry document, so academic authors can ignore it.” It governs any publication reporting company-sponsored research, which means that the academic investigators on such a trial are bound by it from the moment they accept authorship.
  • “Using a medical writer is something to keep quiet about.” GPP3 requires the opposite. Gattrell and colleagues, in BMJ Open, found that trial reports with declared writing support were more completely reported against CONSORT, not less.
  • “GPP 2022 replaced GPP3, so GPP3 no longer matters.” GPP 2022 is an update in the same lineage, and many current SOPs and contracts still name GPP3 explicitly. Authors therefore need to establish which document their agreement cites.
  • “The written agreement is a legal formality for the contracts team.” It is the document that determines, in advance, who may veto a publication and who controls the data, and it is therefore the most consequential item on the list.

Definition and development of GPP3

Good Publication Practice is a guideline for communicating company-sponsored biomedical research. Battisti and colleagues published the third version, GPP3, in Annals of Internal Medicine in 2015, and DeTora and colleagues published the 2022 update in the same journal 6,10. It sits alongside rather than inside the journal-editor instruments: the ICMJE Recommendations set the conditions a journal imposes on a submission, and GPP sets the conditions a sponsor and its collaborators should impose on themselves well before a submission exists 1,10.

The development process is relevant because it explains why the document reads as a consensus statement rather than as advocacy. Battisti and colleagues record that ISMPP invited more than 3,000 publication professionals worldwide to apply for the steering committee or to serve as reviewers 10. The GPP2 authors reviewed 241 applications and formed an 18-member steering committee drawn from 7 countries 10. Of 174 selected reviewers, 94 commented on the second draft, and the steering committee resolved those comments by discussion and consensus 10.

GPP3 also expanded the scope of the guideline, adding new sections on principles for company-sponsored medical research, data sharing, studies that should be published, and plagiarism 10. The last two are the additions most often overlooked: GPP3 takes a position on which studies must be published, not only on how selected studies should be published. The longer history, from the 1998 retreat that initiated it to the 2022 update, is covered on how the GPP standard has changed over time.

3,000+publication professionals invited to apply or review
241applications reviewed for the steering committee
18steering-committee members, drawn from 7 countries
94 of 174selected reviewers who commented on the second draft

How GPP3 was developed. Source: Battisti WP, Wager E, Baltzer L, Bridges D, Cairns A, Carswell CI, et al. Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3. Annals of Internal Medicine.

Four requirements of GPP3 before drafting begins

Most GPP failures encountered in practice are failures of sequence. The most important requirements fall due at the outset, and once a manuscript exists it is usually too late to satisfy them honestly.

A written agreement. Before work begins, the sponsor, the authors and any supporting agency should have a documented agreement covering who the authors are, who controls the data and the final wording, who may delay or stop the publication and on what grounds, and what happens if the parties disagree 10,15. An agreement retrofitted after a draft has circulated is not equivalent, because the question it addresses, namely whether the sponsor can suppress an unfavourable result, can no longer be answered neutrally.

An authorship decision made against criteria. GPP defers to the ICMJE on who qualifies. The ICMJE document, first published in 1978 as the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, sets four authorship criteria, all of which must be met by every author 1,3. GPP3 adds the sponsor-side obligation: the sponsor must not offer authorship as a courtesy, must not condition it on anything other than contribution, and must not exclude a qualifying contributor because of their affiliation 10. The ICMJE Recommendations page examines the four criteria individually.

A registration and disclosure position. For interventional trials, prospective registration is a precondition of publication at ICMJE-member journals, and GPP3 treats the obligation to disclose results as independent of whether the results are commercially welcome 1,29. Where registration applies, it should be completed before enrolment rather than before submission; see trial registration under ICMJE policy.

A substantive publication plan. GPP3 expects a documented plan covering which analyses will be published, in what order, and how the primary report relates to any secondary or subgroup papers. The last of these relationships prevents a legitimate secondary analysis from being read as a duplicate publication.

Requirements of GPP3 during manuscript preparation

Once drafting begins, the obligations are mainly obligations of disclosure; they are inexpensive to meet and costly to omit.

Every contributor who does not qualify for authorship must be named in the acknowledgements, together with their contribution and its funding source 1,10. That includes the medical writer, the statistician who ran the analysis without meeting the four criteria, and the agency that managed the submission. The funding source must be stated, and the sponsor’s role in design, conduct, analysis and the decision to publish must be described rather than merely admitted. Authors must have genuine access to the data and the analyses underpinning the claims to which they attach their names, a point GPP3 makes explicitly because it is the requirement most often conceded in practice and most often queried by editors 10,34.

GPP3 also expects authors to be given sufficient time for review and a genuine opportunity to disagree. A review period of forty-eight hours for a 4,000-word manuscript does not constitute meaningful review, and an editor who enquires how the author list was constructed may also enquire about this. Where the sponsor and an author disagree on interpretation, the disagreement is to be resolved on the science, with the mechanism specified in the written agreement rather than improvised.

Changes introduced by the 2022 update

DeTora and colleagues published GPP 2022 in Annals of Internal Medicine, and ISMPP announced it as an update rather than a replacement of the underlying principles 5,6. Three changes are relevant to routine practice.

First, the framing moved from “company-sponsored medical research” to company-sponsored biomedical research, which brings device, diagnostic and digital-health research unambiguously within its scope 6. An SOP written for drug trials should therefore be re-examined in light of this change.

Second, the update treats the publication as one output among several rather than the endpoint. Plain-language summaries, congress materials, preprints and data-sharing artefacts are handled as part of the same disclosure obligation, which closes a gap often left open in GPP3-era practice, namely a congress abstract managed to a lower standard than the paper it previewed.

Third, it is more explicit about patient and public involvement as a legitimate contribution to be acknowledged, rather than as a courtesy mention.

One caveat applies. Published summaries of GPP 2022 circulate with counts of its sections and recommendations; these counts could not be confirmed from the article itself, which establishes only the fact of the update and its publication in Annals of Internal Medicine. No structural figure that cannot be verified is quoted here. The article itself, rather than a summary, should be consulted before its structure is cited in an SOP.

Distinction between declared writing support and ghostwriting

The distinction GPP3 draws is simple: ghostwriting is undisclosed substantive contribution. Professional writing support that is disclosed, with the funder named, is a declared contribution and is expressly permitted 10,26,30. The confusion persists mainly because the rofecoxib litigation documents, examined by Ross and colleagues in JAMA, caused “medical writer” and “ghostwriter” to appear synonymous in the public record 20. The terms are not synonymous; the distinction lies entirely in whether the role is stated.

There is also evidence on the association between declared support and reporting quality. Gattrell and colleagues, in BMJ Open, examined 233 randomised controlled trial reports 8. Among those with declared professional medical writing support, 39.1% — 43 of 110 — completely reported at least half the assessed CONSORT items, against 21.1% (26 of 123) without support. Adjusting for publication year, the odds of completely reporting at least half the CONSORT items were 1.88 times higher with writing support (95% CI 1.03 to 3.42) 8.

This finding requires careful interpretation. It is a cross-sectional association, the lower limit of the confidence interval lies close to 1, and it provides no information on acceptance, impact or credibility. It does, however, indicate that the common assumption that industry writing support degrades reporting is not supported by the measured reporting 7,8. Item-level detail is provided on what GPP requires you to report and declare.

Drafting an acknowledgement that meets editorial expectations

The acknowledgement is where GPP compliance becomes visible to an editor, and it is the most common point at which an otherwise compliant publication gives the impression that something is being managed. The usual failure is not dishonesty but vagueness. The phrase “Editorial assistance” describes both a proofread and a complete first draft, which is precisely why editors query it.

An effective acknowledgement names the individual, their employer, their contribution and its funder, in that order and in a single sentence. It requires approximately thirty words.

The same writing support, acknowledged two ways

Invites the query

The authors would like to thank all those who contributed to this study. Editorial assistance was provided during the preparation of this manuscript.

Who provided it? No name or affiliation is given, so the contribution cannot be assessed.

What did ‘assistance’ mean? The term applies equally to a proofread and to a complete first draft, as editors are aware.

Who paid? The funder is not stated, although this is precisely the disclosure GPP exists to compel.

Did the authors see the data? Data access is not addressed, so the standard editorial query follows.

Answers it in advance

Medical writing support, including development of an outline and first draft under the authors’ direction, incorporation of author comments, assembly of tables and figures, referencing, copyediting and submission, was provided by Jane Okafor, PhD, of Meridian Scientific Communications, and was funded by Northvale Therapeutics in accordance with Good Publication Practice. All authors had full access to the study data, contributed to interpretation, approved the final manuscript and are accountable for its accuracy and integrity.

The writer is named with her degree and employer, so the role is attributable.

The scope is itemised — outline, first draft, figures, submission — so that it need not be inferred.

The funder is named and GPP is cited, which is the compliance statement an editor is looking for.

Data access and author accountability are stated, pre-empting the ICMJE criterion-four question.

Neither version is more honest in intent; the second is simply verifiable. Declared support is permitted under GPP3 and associated with more complete CONSORT reporting in Gattrell and colleagues’ data, so there is no defensive reason for vagueness; it is vagueness, not disclosure, that creates suspicion.

Enforcement of individual GPP3 requirements

It is useful to establish where each requirement is enforced, because this indicates which omissions carry consequences and which do not.

A journal can enforce authorship criteria, contributorship statements, funding and conflict disclosure, trial registration, and the absence of redundant publication — because each of those is a submission condition it checks 1,4. A journal cannot see the written agreement, the publication plan, the review timelines, or whether an unfavourable study was never written up. Those are enforceable only by the sponsor’s own governance: SOPs, training, contract language with agencies, and audit. That asymmetry is why getting GPP adopted inside an organisation is a different and more difficult problem than complying with a journal’s instructions to authors.

It is also why publication non-disclosure is the GPP failure with the weakest external check. Antes and Chalmers argued in the Lancet that under-reporting of clinical trials is unethical, and Stern and Simes showed in BMJ that delayed publication tracks with unwelcome results 33. No editor can query a paper that has not been submitted.

Which GPP3 requirements a journal can check, and which only you can

RequirementChecked by the journal?What actually enforces it
Authorship meets all four ICMJE criteriaYes — contributorship statement at submissionJournal policy; corrections and authorship disputes
All non-author contributors acknowledged, with funder namedYes — acknowledgement sectionEditor query; post-publication correction
Funding source and sponsor’s role declaredYes — disclosure formsJournal policy; ICMJE disclosure requirement
Prospective trial registrationYes — registration number verifiedICMJE-member journals refuse unregistered trials
Written agreement before work beginsNo — never seen by the journalSponsor SOP, contract language, internal audit
Authors given adequate review time and genuine ability to dissentNoSponsor SOP; author willingness to refuse
Studies that should be published are publishedNo — a journal cannot see an unsubmitted paperInternal governance; registry results posting

Requirements as set out by Battisti and colleagues in Annals of Internal Medicine (GPP3) and DeTora and colleagues in Annals of Internal Medicine (GPP 2022). The enforcement column is our reading of what a journal can and cannot observe at submission, not a statement from either guideline.

Matters that GPP3 leaves unresolved

Three matters remain unresolved, and treating them as settled is unproductive.

GPP does not specify where the boundary lies between acceptable sponsor review and editorial control. It requires that authors retain final say on content, and it requires the mechanism to be documented, but the practical boundary — how many rounds of sponsor comment on interpretation is too many — remains a matter of judgement in each case 10.

It does not resolve the status of the publication steering committee. These bodies make real decisions about sequencing and framing, and their members frequently do not meet the four ICMJE criteria for any individual paper. GPP3 asks for transparency about the structure; it does not say how to credit it.

Finally, the evidence on whether GPP adherence changes outcomes is limited. The reporting-quality work by Gattrell and colleagues and by Mills and colleagues in F1000Research is about writing support, not about GPP compliance as such 7,8. No study has yet determined whether a GPP-compliant programme produces a more trustworthy literature than a non-compliant one, and the design of such a study is not straightforward. GPP is best regarded as a defensible process standard, which is what it claims to be, rather than as a demonstrated quality intervention.

Key points

Key points

GPP3 is a sequence of requirements rather than a statement of sentiment. The requirements that carry the most weight — a written agreement, an authorship decision made against the four ICMJE criteria, a registration and disclosure position, and a substantive publication plan — all fall due before drafting and cannot be honestly satisfied afterwards. GPP 2022 retained that architecture and extended it to biomedical research and to non-journal outputs such as plain-language summaries and congress materials. Only a small part of GPP can be enforced by a journal; most of it is enforceable only through an organisation’s own SOPs, which is why adoption is the principal challenge.

Application to your study

Application to your study

  1. Establish which document the contract names. GPP3, GPP 2022, or “GPP” unqualified. If the contract specifies GPP3, that remains the applicable standard until the contract is amended.
  2. Locate the written agreement before accepting authorship. If none exists, the agreement, not the manuscript, is the first deliverable. The agreement should be checked specifically for who may delay or veto publication, and on what grounds.
  3. Assess each proposed author against all four ICMJE criteria, in writing. All four criteria apply to every author. A record of the criteria each contributor did not meet forms the basis of the acknowledgements.
  4. Name every non-author contributor with their employer and funder. This includes writers, statisticians, agencies and patient contributors. The phrase “editorial assistance” alone commonly generates queries.
  5. State the sponsor’s role rather than its existence. The statement should specify which of design, conduct, analysis and the decision to publish involved the sponsor.
  6. Confirm that authors had genuine access to the data before stating that they did. If an author has seen only a summary table, the accountability statement is not yet accurate.
  7. Map the paper against the remainder of the programme. If this is a secondary or subgroup analysis, cross-reference the primary report explicitly in the abstract and methods.
  8. Verify the length of the review period. If authors are given only days to review a full manuscript, the GPP requirement for meaningful review is not met, irrespective of the provisions of the SOP.

Frequently asked questions

There are four principal requirements. A documented written agreement between sponsor, authors and agency before work begins, covering data control and who may stop a publication. A publication plan showing how each paper relates to the others from the same programme. Meaningful author review time and a mechanism for resolving disagreement on interpretation. And an obligation to publish studies that should be published, including ones with unwelcome results. None of these is visible to a journal at submission, which is why they depend on an organisation’s own SOPs and contract language rather than on editorial enforcement.

GPP 2022, published by DeTora and colleagues in Annals of Internal Medicine, is the current version in that lineage, and it is an update rather than a reversal — the authorship, acknowledgement, disclosure and publication-obligation architecture carries over. In practice both remain relevant, because many current SOPs, master service agreements and agency statements of work still name GPP3 by version. Authors should establish which document their own contract cites rather than assume. Where the two differ, the main changes are the move to “biomedical” research, broader coverage of non-journal outputs, and more explicit treatment of patient involvement.

Yes, and the disclosure should name the individual, their employer, what they did and who funded it. Undisclosed substantive contribution is ghostwriting; disclosed support is a permitted and normal contribution. There is no defensive reason for vagueness: Gattrell and colleagues, in BMJ Open, found that among 233 randomised trial reports, 39.1% of those with declared writing support completely reported at least half the assessed CONSORT items against 21.1% without — an adjusted odds ratio of 1.88 (95% CI 1.03 to 3.42). Vague phrasing such as “editorial assistance was provided” is what prompts editor queries.

No figure is given here. Counts circulate in secondary summaries, but only the update’s existence and its publication in Annals of Internal Medicine could be confirmed from the article itself, not its internal structure. Anyone citing the structure of GPP 2022 in an SOP or a training deck should read the article and count the elements directly; a structural figure quoted from a press summary is precisely the kind of unverified detail that exposes a policy document to later criticism.

Authorship is restricted to those who meet all four ICMJE authorship criteria. GPP defers to the ICMJE on this. The ICMJE document, first issued in 1978 as the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, requires every author to satisfy every criterion — substantial contribution, drafting or critical revision, final approval, and accountability for the whole work. Employment by the sponsor neither qualifies nor disqualifies anyone. What GPP3 adds is the sponsor-side duty: authorship must not be offered as a courtesy, withheld as leverage, or conditioned on anything other than contribution.

This has not been demonstrated, and the gap should be acknowledged. The evidence that exists is about declared professional writing support rather than GPP compliance itself — Gattrell and colleagues in BMJ Open on CONSORT completeness, and Mills and colleagues in F1000Research on abstract reporting quality. No study compares GPP-compliant with non-compliant publication programmes, and designing one would be difficult, since compliance is not randomly assigned. GPP is best regarded as a defensible process standard, which is what it claims to be, rather than as a demonstrated quality intervention.

That is precisely what the written agreement is supposed to have settled in advance. GPP3 permits legitimate delay — for patent filing or regulatory sequencing, for instance — where the grounds and the maximum period are specified beforehand. What it does not permit is suppression because the result is commercially unwelcome. If no written agreement exists and the question arises during manuscript development, the parties are negotiating without a standard, which is the position the requirement exists to prevent. Antes and Chalmers argued in the Lancet that under-reporting of trials is unethical; Stern and Simes showed in BMJ that publication delay tracks with unfavourable findings.

References

  1. International Committee of Medical Journal Editors. Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. ICMJE. 2026. read 9 October 2026. icmje.org
  2. Committee on Publication Ethics. Text recycling guidelines. COPE. 2013. read 9 October 2026. par.nsf.gov
  3. International Committee of Medical Journal Editors. The New ICMJE Recommendations (August 2013). ICMJE. 2013. read 9 October 2026. icmje.org
  4. Committee on Publication Ethics. Core Practices. COPE. read 9 October 2026. equator-network.org
  5. International Society for Medical Publication Professionals. GPP 2022: Good Publication Practice guidelines for company-sponsored biomedical research published in Annals of Internal Medicine (press release). ISMPP. 2022. read 9 October 2026. ismpp.org
  6. DeTora LM, Toroser D, Sykes A, Vanderlinden C, Plunkett FJ, Lane T, Hanekamp E, Dormer L, DiBiasi F, Bridges D, Baltzer L, Citrome L. Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update. Annals of Internal Medicine. 2022;175(9):1298-1304. doi:10.7326/M22-1460 read 9 October 2026. doi.org/10.7326/M22-1460
  7. Mills I, Sheard C, Hays M, Douglas K, Winchester CC, Gattrell WT. Professional medical writing support and the reporting quality of randomized controlled trial abstracts among high-impact general medical journals. F1000Research. 2017;6:1489. doi:10.12688/f1000research.12268.2 read 9 October 2026. doi.org/10.12688/f1000research.12268.2
  8. Gattrell WT, Hopewell S, Young K, Farrow P, White R, Wager E, Winchester CC. Professional medical writing support and the quality of randomised controlled trial reporting: a cross-sectional study. BMJ Open. 2016;6(2):e010329. doi:10.1136/bmjopen-2015-010329 read 9 October 2026. doi.org/10.1136/bmjopen-2015-010329
  9. Roig M; US Office of Research Integrity. Avoiding plagiarism, self-plagiarism, and other questionable writing practices: a guide to ethical writing. US Office of Research Integrity. 2015. read 9 October 2026. equator-network.org
  10. Battisti WP, Wager E, Baltzer L, Bridges D, Cairns A, Carswell CI, Citrome L, Gurr JA, Mooney LA, Moore BJ, Pena T, Sanes-Miller CH, Veitch K, Woolley KL, Yarker YE. Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3. Annals of Internal Medicine. 2015;163(6):461-464. doi:10.7326/M15-0288 read 9 October 2026. doi.org/10.7326/M15-0288
  11. Fang FC, Steen RG, Casadevall A. Misconduct accounts for the majority of retracted scientific publications. Proceedings of the National Academy of Sciences of the USA. 2012;109(42):17028-17033. doi:10.1073/pnas.1212247109 read 9 October 2026. doi.org/10.1073/pnas.1212247109
  12. Wislar JS, Flanagin A, Fontanarosa PB, et al. Honorary and ghost authorship in high impact biomedical journals: a cross sectional survey. BMJ. 2011;343:d6128. doi:10.1136/bmj.d6128 read 9 October 2026. doi.org/10.1136/bmj.d6128
  13. Das N, Panjabi M. Plagiarism: why is it such a big issue for medical writers? Perspectives in Clinical Research. 2011;2(2):67-71. doi:10.4103/2229-3485.80370 read 9 October 2026. doi.org/10.4103/2229-3485.80370
  14. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Annals of Internal Medicine. 2010;152:726-732. read 9 October 2026. care-statement.org
  15. Graf C, Battisti WP, Bridges D, Bruce-Winkler V, Conaty JM, Ellison JM, Field EA, Gurr JA, Marx M-E, Patel M, Sanes-Miller C, Yarker YE. Good publication practice for communicating company sponsored medical research: the GPP2 guidelines. BMJ. 2009;339:b4330. doi:10.1136/bmj.b4330 read 9 October 2026. doi.org/10.1136/bmj.b4330
  16. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine. 2009;6:e1000097. read 9 October 2026. care-statement.org
  17. Woloshin S, Schwartz LM, Casella SL, Kennedy AT, Larson RJ. Press releases by academic medical centers: not so academic? Annals of Internal Medicine. 2009;150:613-618. read 9 October 2026. archive.emwa.org
  18. Rothman DJ, McDonald WJ, Berkowitz CD, Chimonas SC, DeAngelis CD, Hale RW, et al. Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. JAMA. 2009;301(13):1367-1372. read 9 October 2026. equator-network.org
  19. Gotzsche PC, Kassirer JP, Woolley KL, Wager E, Jacobs A, Gertel A, et al. What should be done to tackle ghostwriting in the medical literature? PLoS Medicine. 2009;6(2):e1000023. read 9 October 2026. archive.emwa.org
  20. Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA. 2008;299:1800-1812. read 9 October 2026. archive.emwa.org
  21. Angell M. Industry-sponsored clinical research: a broken system. JAMA. 2008;300:1069-1071. read 9 October 2026. archive.emwa.org
  22. Titus SL, Wells JA, Rhoades LJ. Repairing research integrity. Nature. 2008;453:980-982. read 9 October 2026. archive.emwa.org
  23. Hill KP, Ross JS, Egilman DS, Krumholz HM. The ADVANTAGE seeding trial: a review of internal documents. Annals of Internal Medicine. 2008;149:251-258. read 9 October 2026. archive.emwa.org
  24. Norris R, Bowman A, Fagan JM, Gallagher ER, Geraci AB, Gertel A, et al. International Society for Medical Publication Professionals (ISMPP) position statement. Current Medical Research and Opinion. 2007;23:1837-1840. read 9 October 2026. archive.emwa.org
  25. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335:806-808. read 9 October 2026. care-statement.org
  26. Jacobs A, Wager E. EMWA guidelines on the role of medical writers in developing peer-reviewed publications. Current Medical Research and Opinion. 2005;21:317-321. read 9 October 2026. archive.emwa.org
  27. von Elm E, Poglia G, Walder B, Tramer MR. Different patterns of duplicate publication: an analysis of articles used in systematic reviews. JAMA. 2004;291(8):974-980. doi:10.1001/jama.291.8.974 read 9 October 2026. doi.org/10.1001/jama.291.8.974
  28. DeAngelis CD. Duplicate publication, multiple problems. JAMA. 2004;292:1745-1746. doi:10.1001/jama.292.14.1745 read 9 October 2026. doi.org/10.1001/jama.292.14.1745
  29. Steinbrook R. Public registration of clinical trials. New England Journal of Medicine. 2004;351:315-317. doi:10.1056/NEJMp048191 read 9 October 2026. doi.org/10.1056/NEJMp048191
  30. Hamilton CW, Royer MG; AMWA 2002 Task Force on the Contributions of Medical Writers to Scientific Publications. AMWA position statement on the contributions of medical writers to scientific publications. AMWA Journal. 2003;18:13-16. read 9 October 2026. archive.emwa.org
  31. Wager E, Field EA, Grossman L. Good publication practice for pharmaceutical companies. Current Medical Research and Opinion. 2003;19(3):149-154. doi:10.1185/030079903125001767 read 9 October 2026. doi.org/10.1185/030079903125001767
  32. Wager E, Field EA, Grossman L. Good publication practice for pharmaceutical companies: why we need another set of guidelines. Current Medical Research and Opinion. 2003;19(3):147-148. read 9 October 2026. ismpp.org
  33. Antes G, Chalmers I. Under-reporting of clinical trials is unethical. Lancet. 2003;361:978-979. read 9 October 2026. ismpp.org
  34. Davidoff F, DeAngelis CD, Drazen JM, Hoey J, Hojgaard L, Horton R, et al. Sponsorship, authorship, and accountability. Annals of Internal Medicine. 2001;135:463-466. read 9 October 2026. ismpp.org
  35. Rennie D, Flanagin A, Yank V. The contributions of authors. JAMA. 2000;284:89-91. read 9 October 2026. ismpp.org

Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.

How to cite this article

Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.

Pubrica Academy. (2026, October 9). Good Publication Practice: The Requirements of GPP3 and the Changes Introduced in GPP 2022. Pubrica. https://pubrica.com/academy/publication-ethics/use-of-gpp3-for-ethical-guidance/

This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.

GPP3 pre-drafting checklist

This checklist should be completed before the first draft rather than before submission. The items are listed in the order in which they fall due, and any item that cannot be checked is one that cannot be remedied later. The completed checklist should be retained in the publication file, because the value of a process standard lies in the existence of the record.

GPP PRE-DRAFTING CHECKLIST
Study / programme: ______________________   Publication: ______________________
Guideline version named in the contract:  [ ] GPP3   [ ] GPP 2022   [ ] "GPP" unqualified

1. WRITTEN AGREEMENT  (due before any work begins)
   [ ] Agreement exists, dated, signed by sponsor / authors / agency
   [ ] Names who controls the data and who has final say on wording
   [ ] States who may delay or stop publication, on what grounds, for how long
   [ ] States how disagreement on interpretation is resolved
   Document reference: ______________________

2. AUTHORSHIP  (all four ICMJE criteria, every author)
   For each proposed author, record YES/NO against each criterion:
     Name ____________  substantial contribution __  drafting/revision __
                        final approval __  accountable for whole work __
   [ ] Everyone who failed a criterion has been moved to acknowledgements
   [ ] No author was added for seniority, affiliation or courtesy
   [ ] No qualifying contributor was excluded because of their employer

3. REGISTRATION AND DISCLOSURE
   [ ] Interventional study registered at or before first enrolment
       Registry / number: ______________________
   [ ] Results-disclosure obligation identified and dated
   [ ] Decision to publish is not conditional on the direction of the result

4. PUBLICATION PLAN
   [ ] Primary report identified and its status known
   [ ] This paper's relationship to the primary report is written down
   [ ] If secondary / subgroup: the cross-reference wording is drafted now
   [ ] Congress abstracts and plain-language summaries from these data listed

5. ACKNOWLEDGEMENT TEXT  (draft it now, not at submission)
   Writer: name ______________  degree ____  employer ______________
   Scope: [ ] outline [ ] first draft [ ] revision [ ] figures
          [ ] referencing [ ] copyediting [ ] submission
   Funded by: ______________________
   [ ] Statistician / other non-author contributors named with role and funder
   [ ] Patient or public contributors named, with consent to be named
   [ ] Sponsor's role stated as design / conduct / analysis / decision to publish

6. AUTHOR CONDITIONS
   [ ] Every author has, or will have, access to the data behind the claims
   [ ] Review window agreed and realistic for the manuscript length
   [ ] Authors know they may dissent, and how that is recorded

Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.

How Pubrica can help

Pubrica’s medical writing team works to GPP and, as a matter of course, names itself in the acknowledgements together with the funder. Where a programme is already under way without a written agreement or a settled author list, the team states this plainly and assists in reconstructing what can honestly be reconstructed rather than obscuring the gap. The team also drafts the acknowledgement, contributorship and sponsor-role statements that editors query most often.

Find something else

Search the Pubrica Academy

Access is free and requires no account. Enter a topic, or open the full library to filter by category, sub-topic or resource type.

Pubrica can review the protocol and the draft author list and identify any point at which the GPP sequence has already been broken.

A scoping assessment is free and takes two business days. It provides a written assessment of what the work requires and which specialist would undertake it.

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.